In contrast, tocilizumab, through the collateral modulation of STAT1, preferably modulates FCGR1 activity, which is involved in neutrophil activation, a relevant hallmark in Still’s disease [11]. The gene discussed is FCGR1A; the disease is systemic-onset juvenile idiopathic arthritis.